Jäger W, Wildt L, Lang N
Universitäts-Frauenklinik der Friedrich-Alexander-Universität Erlangen-Nürnberg.
Geburtshilfe Frauenheilkd. 1989 Jul;49(7):611-7. doi: 10.1055/s-2008-1026665.
Previous observations in healthy women showed, that the increase of CA-125 observed during progression of ovarian cancer could be dependent on pituitary gonadotropins. Therefore, the GnRH-analog D-Trp 6-LH-RH was administered to 17 patients with progressive ovarian cancer and increasing CA-125 serum levels. 12 of 17 patients who had been treated for more than three months exhibited a considerably slower increase of CA-125 which was associated with a remarkable stabilisation of disease. The other patients, who suffered from progressive disease, an increase of the gonadotropins could be detected during the analog treatment. These observations strengthen the suspicion of the critical role of gonadotropins in the production of CA-125 and the progression of ovarian cancer.
先前对健康女性的观察表明，在卵巢癌进展过程中观察到的CA - 125升高可能依赖于垂体促性腺激素。因此，对17例卵巢癌进展且CA - 125血清水平升高的患者给予GnRH类似物D - Trp 6 - LH - RH。17例接受治疗超过三个月的患者中，有12例CA - 125升高明显减缓，这与疾病的显著稳定相关。其他患有疾病进展的患者，在类似物治疗期间可检测到促性腺激素升高。这些观察结果强化了对促性腺激素在CA - 125产生及卵巢癌进展中关键作用的怀疑。
